- Report
- April 2025
- 50 Pages
Global
From €2502EUR$2,650USD£2,146GBP
Clobenztropine is a respiratory drug used to treat asthma and other respiratory conditions. It is a long-acting muscarinic antagonist (LAMA) that works by blocking the action of acetylcholine, a chemical messenger in the body that causes the muscles in the airways to constrict. Clobenztropine is used to reduce the frequency and severity of asthma attacks and to improve lung function. It is also used to treat chronic obstructive pulmonary disease (COPD).
Clobenztropine is available in both oral and inhalation forms. The oral form is taken once daily and the inhalation form is taken twice daily. The inhalation form is more effective than the oral form in controlling asthma symptoms.
Clobenztropine is a relatively new drug and is not widely used. It is not yet approved by the FDA for use in the United States. However, it is approved in some other countries, including Canada, Australia, and the United Kingdom.
Some companies in the Clobenztropine market include GlaxoSmithKline, AstraZeneca, Merck, and Boehringer Ingelheim. Show Less Read more